STAT

Opinion: Peer review could have helped short-circuit the Theranos fake news scandal

Thanks to Theranos, startups might now face a greater burden of proof to demonstrate their technology is effective.
Source: Kristoffer Tripplaar/AP

Theranos had a product almost everyone could get behind: a revolutionary blood test that would allow individuals to quickly and easily access information about their health. Startups like Theranos rely on cutting-edge innovation, then leverage that innovation to attract investors. Now the company’s downfall is a signal to innovators, the public, and the media that we need more transparency and credibility built on peer-reviewed publications.

Holmes, who was accused of falsely claiming that Theranos had developed a portable analyzer that could perform virtually any medical test using with the Security and Exchange Commission for a penalty of $500,000, among other things.

You’re reading a preview, subscribe to read more.

More from STAT

STAT1 min read
STAT+: IVF Doctors Demand Full Details On Fluid That Grows Embryos Amid CooperSurgical Lawsuits
Patients from all over the country are filing lawsuits against medical supply giant CooperSurgical, alleging that fluid the company sent to in vitro fertilization clinics destroyed their embryos. The fluid, called culture media, is filled with nutrie
STAT1 min read
Disparities In Donor Acceptance Rates Point To Need For More Equitable Heart Transplant Care
While access to donor hearts has increased, there are still gender- and race-based disparities in the acceptance rate of a donor heart offer by transplant teams, a new study finds.
STAT1 min read
STAT+: AstraZeneca Sues Arkansas Over The Role Of Pharmacies In A Federal Discount Drug Program
AstraZeneca filed a lawsuit seeking to block an Arkansas law that requires the company to ship its medicines to any pharmacy working with hospitals participating in a federal discount program.

Related Books & Audiobooks